To amend sections 3902.50 and 3902.70; to amend, for the purpose of adopting a new section number as indicated in parentheses, section 3902.72 (3902.75); and to enact new section 3902.72 of the Revised Code to prohibit drug manufacturers from taking certain actions regarding reimbursements made to 340B covered entities.
Impact
If enacted, this bill would significantly impact the operational landscape for healthcare providers and covered entities involved in the 340B program by reinforcing their ability to obtain medications without unwarranted restrictions. This focused protection seeks to ensure that the benefits of the 340B program reach the intended patient populations effectively. Furthermore, it introduces substantial penalties for non-compliance, potentially leading to increased accountability among manufacturers and pharmacy benefit managers who might otherwise impose burdensome conditions.
Summary
House Bill 276 aims to amend various sections of the Ohio Revised Code to enhance the protections for 340B covered entities against certain restrictive practices by drug manufacturers and pharmacy benefit managers. The bill prohibits these parties from denying, restricting, or discriminating against the acquisition and delivery of drugs acquired under the federal 340B drug pricing program. Additionally, it addresses the requirement for claims or utilization data sharing as a condition for accessing these drugs, thereby streamlining the process for covered entities in obtaining necessary medications for their patients.
Sentiment
The sentiment surrounding HB 276 appears to be largely supportive among healthcare advocates, who argue that the bill is a necessary step toward protecting vulnerable populations that rely on the medications obtained through the 340B program. Proponents believe that the bill encourages better access to affordable medication and aligns with the overarching objectives of the 340B initiative. However, there may be concerns from some factions within the pharmaceutical and insurance industries regarding the implications of increased regulation and the potential impacts on pricing and availability of certain drugs.
Contention
Notable points of contention may arise from the inclusion of strict penalties for violations of the provisions outlined in the bill. The imposition of hefty fines for non-compliance could lead to debates about the balance between regulation and operational flexibility for drug manufacturers. Additionally, discussions may focus on the potential unintended consequences that could emerge from tightening access requirements, prompting scrutiny of how such measures could affect drug pricing and availability more broadly in the healthcare market.
To amend sections 3517.12, 3517.13, and 3517.155 of the Revised Code to modify the Campaign Finance Law regarding foreign nationals and statewide initiatives and referenda and to declare an emergency.
To amend sections 3517.12, 3517.13, and 3517.155 of the Revised Code to modify the Campaign Finance Law regarding foreign nationals and statewide initiatives and referenda and to declare an emergency.
To amend sections 3505.01 and 3505.10 of the Revised Code to modify the deadline for a political party to certify its nominees for President and Vice-President to the Secretary of State.
To delay the deadline for a major political party to certify its presidential and vice presidential candidates to the Secretary of State for the 2024 general election.